Author

Grygoriy Ursol

Observed names: G Ursol, G. Ursol, Grygorii Mykolaiovych Ursol, Grygorii Ursol

OpenAlex ID: A5012432808

Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial

2019 · Tony S K Mok, Yi-Long Wu, et al. · The Lancet · 3,309

OA15.04 Association Between KRAS/STK11/KEAP1 Mutations and Outcomes in POSEIDON: Durvalumab ± Tremelimumab + Chemotherapy in mNSCLC

2022 · S. Peters, B.C. Cho, et al. · Journal of Thoracic Oncology · 33

Efficacy and Safety of Masitinib in Corticosteroid-Dependent Severe Asthma: A Randomized Placebo-Controlled Trial

2022 · Lavinia Davidescu, Grygoriy Ursol, et al. · Journal of Asthma and Allergy · 29

PDF

1235TiP Perioperative pembrolizumab + platinum-based chemotherapy for resectable locally advanced non-small cell lung cancer: The phase III KEYNOTE-671 study

2020 · M. Tsuboi, A. Luft, et al. · Annals of Oncology · 26

80O Atezolizumab (atezo) vs best supportive care (BSC) in stage II-IIIA NSCLC with high PD-L1 expression: Sub-analysis from the pivotal phase III IMpower010 study

2022 · E. Felip, N.K. Altorki, et al. · Annals of Oncology · 14

375O Final efficacy results from IMpower132: First-line atezolizumab + chemotherapy in patients with stage IV non-squamous NSCLC

2020 · M. Nishio, F. Barlesi, et al. · Annals of Oncology · 11

PDF

LBA59 Durvalumab (D) ± tremelimumab (T) + chemotherapy (CT) in 1L metastatic (m) NSCLC: Overall survival (OS) update from POSEIDON after median follow-up (mFU) of approximately 4 years (y)

2022 · M. Johnson, B.C. Cho, et al. · Annals of Oncology · 7

PDF

Phase 2 study of PD-1 inhibitor JTX-4014 alone and in combination with vopratelimab, an ICOS agonist, in biomarker-selected subjects with metastatic NSCLC after one prior platinum-containing regimen (SELECT).

2021 · Oleh Kobziev, Iurie Bulat, et al. · Journal of Clinical Oncology · 6

1312MO Combining the antigen-presenting cell activator eftilagimod alpha (soluble LAG-3) and pembrolizumab: Overall survival data from the first line non-small cell lung carcinoma (NSCLC) cohort of TACTI-002 (phase II)

2023 · E. Carcereny, E. Felip, et al. · Annals of Oncology · 5

PDF

LBA3 Durvalumab (D) ± tremelimumab (T) + chemotherapy (CT) in first-line (1L) metastatic NSCLC (mNSCLC): 5-year (y) overall survival (OS) update from the POSEIDON study

2023 · S. Peters, B.C. Cho, et al. · Immuno-Oncology Technology · 4

PDF

222MO Exploratory analysis of participants without pathological complete response (pCR) in the KEYNOTE-671 study of perioperative pembrolizumab (pembro) in early-stage NSCLC after 5 years of follow-up

2026 · M. Reck, C. Grohe, et al. · ESMO Open · 3

4MO Updated results for MK-1084 + pembrolizumab in KRAS G12C-mutated (mut) metastatic non-small cell lung cancer (mNSCLC) enrolled in KANDLELIT-001

2026 · A.G. Sacher, Y. Rottenberg, et al. · ESMO Open · 3

PDF

EP08.01-027 Durvalumab (D) ± Tremelimumab (T) + Chemotherapy (CT) in 1L Metastatic NSCLC: Outcomes by Tumour PD-L1 Expression in POSEIDON

2022 · E.B. Garon, B.C. Cho, et al. · Journal of Thoracic Oncology · 3

PDF

5MO Patient reported outcomes (PROs) with 1L durvalumab (D), with or without tremelimumab (T), plus chemotherapy (CT) in metastatic (m) NSCLC: Results from POSEIDON

2022 · E.B. Garon, B.C. Cho, et al. · Annals of Oncology · 3

PDF

326P Durvalumab (D) ± tremelimumab (T) + chemotherapy (CT) in 1L metastatic (m) NSCLC: Overall survival (OS) update from POSEIDON after median follow-up (mFU) of approximately 4 years (y)

2022 · B.C. Cho, A. Luft, et al. · Annals of Oncology · 2

Pharmacokinetics, safety, and efficacy of an alternative dosing regimen of sasanlimab in participants with advanced NSCLC and other malignancies

2024 · Konstantin Penkov, Igor Bondarenko, et al. · Therapeutic Advances in Medical Oncology · 1

12MO Patterns of response in metastatic (m) NSCLC after 2 and 4 cycles of chemotherapy (CT), alone or with durvalumab (D) ± tremelimumab (T), in the phase III POSEIDON study

2023 · N. Reinmuth, B.C. Cho, et al. · Journal of Thoracic Oncology · 1

PDF

Durvalumab +/− Tremelimumab + Chemotherapy as First-line Treatment for mNSCLC: Results from the Phase III POSEIDON Study

2022 · N Reinmuth, M L Johnson, et al. · Pneumologie · 1

6RO Calderasib (MK-1084) for KRAS G12C-mutated (mut) advanced colorectal cancer (CRC): Results from KANDLELIT-001

2026 · R. Dziadziuszko, V. Moreno Garcia, et al. · Annals of Oncology

PDF

MA04.04 Perioperative Pembrolizumab in Non-Small Cell Cancer (NSCLC): 4-Year Outcomes by Nodal Status in the KEYNOTE-671 Study

2025 · H. Wakelee, I. Demedts, et al. · Journal of Thoracic Oncology

438 | Orelabrutinib for the Treatment of Relapsed/refractory Mantle Cell Lymphoma: Efficacy and Safety Results From a Global Phase 1/2 Study

2025 · Y. Wang, J. D'Olimpio, et al. · Hematological Oncology

PDF

Works count: 21

Citation count: 3,461

H-index: 7

I10-index: 6